Kenshi Suzuki
- Hematology top 0.5%
- Multiple Myeloma Research and Treatments 127
- Acute Myeloid Leukemia Research 18
- Oncology top 2%
- Peptidase Inhibition and Analysis 42
- Cancer Treatment and Pharmacology 24
- Genetics top 2%
- Chronic Lymphocytic Leukemia Research 28
- Immunology top 2%
- Aging top 5%
-
- Protein Degradation and Inhibitors 45
- Amyloidosis: Diagnosis, Treatment, Outcomes 23
- DNA Repair Mechanisms 22
- Co-authors
- Masanori OkanishiHitoshi UmezawaYasunori NakagawaAndrew J. NicolMie NiedaKatsuiku HirokawaMasanobu KitagawaPhilippe Moreau
- Cited by
- HematologyOncologyGenetics
- Partner nations
- JapanUnited StatesUnited Kingdom
In The Last Decade
Kenshi Suzuki
251 papers receiving 4.4k citations
Hit Papers
Peers
Comparison fields: 5 of 138
- Hematology 1.7k
- Oncology 1.6k
- Genetics 483
- Immunology 952
- Aging 78
Countries citing papers authored by Kenshi Suzuki
This map shows the geographic impact of Kenshi Suzuki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenshi Suzuki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenshi Suzuki more than expected).
Fields of papers citing papers by Kenshi Suzuki
This network shows the impact of papers produced by Kenshi Suzuki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenshi Suzuki. The network helps show where Kenshi Suzuki may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Kenshi Suzuki, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 0 | |
| 4 | 2024 | 2 | |
| 5 | 2024 | 5 | |
| 6 | 2023 | 15 | |
| 7 | 2022 | 22 | |
| 8 | 2022 | 1 | |
| 9 | 2022 | 12 | |
| 10 | 2021 | 2 | |
| 11 | 2020 | 12 | |
| 12 | 2020 | 60 | |
| 13 | 2019 | 6 | |
| 14 | 2017 | 14 | |
| 15 | 2017 | 0 | |
| 16 | 2009 | 43 | |
| 17 | Development of Tele-existence Visual Display System for Humanoid Robot Control | 2002 | 3 |
| 18 | Clinical evaluation of combination therapy with tobramycin and ceftazidime for severe infections associated with hematological disorders | 1993 | 1 |
| 19 | Avian Malaria-like Disease Found in Young Cranes : Grus monacha | 1984 | 2 |
| 20 | Light-and Electron Microscopic Observations of a Strain of Free-living Nematodes, Rhabditidae tokai | 1979 | 1 |
About Kenshi Suzuki
Kenshi Suzuki is a scholar working on Hematology, Aging and Genetics, having authored 270 papers that have together received 4.5k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (127 papers), Protein Degradation and Inhibitors (45 papers), Peptidase Inhibition and Analysis (42 papers), Chronic Lymphocytic Leukemia Research (28 papers), Cancer Treatment and Pharmacology (24 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (23 papers), DNA Repair Mechanisms (22 papers) and Acute Myeloid Leukemia Research (18 papers). The work is most often cited by research in Hematology (1.7k citations), Oncology (1.6k citations) and Genetics (483 citations). Kenshi Suzuki has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Masanori Okanishi, Hitoshi Umezawa, Yasunori Nakagawa, Andrew J. Nicol, Mie Nieda, Katsuiku Hirokawa, Masanobu Kitagawa, Philippe Moreau, Kiyoshi Yokokawa and Maki Hasegawa. Their work appears in journals such as Nature, New England Journal of Medicine and Nucleic Acids Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.